Salus BioMed is at the forefront of genetic sequencing and spatial omics technologies, focusing on innovative solutions that cater to various applications in healthcare and research. Their core technologies include high-throughput sequencing (NGS) and advanced spatial transcriptomics, which enable precise analysis of genetic material and cellular environments. The Saluseq Nimbo sequencing platform exemplifies their commitment to speed and accuracy, utilizing a combination of in-situ amplification and high-resolution imaging to deliver reliable genomic data. This platform is particularly suited for applications in infectious disease and oncology, providing critical insights for targeted therapies.

In addition to their sequencing capabilities, Salus BioMed offers a range of clinical applications, including non-invasive prenatal testing (NIPT), preimplantation genetic testing (PGT-A), and copy number variation sequencing (CNV-Seq). These technologies leverage NGS to enhance diagnostic accuracy and efficiency in identifying genetic abnormalities and hereditary conditions. Salus BioMed's focus on integrating cutting-edge technologies with practical applications positions them as a leader in the life sciences sector, driving advancements in personalized medicine and genetic research.

China

Founded in Shenzhen, Salus Biomed specializes in developing high-throughput genetic sequencing platforms and is a world leader in super-resolution spatial omics research platforms, serving both research and clinical applications. With a proven track record and over 100 clients worldwide, Salus Biomed is dedicated to providing a range of cutting-edge instruments and solutions to the sequencing and life sciences industry. This empowers users across various industry and academic research applications.

Salus BioMed

Company Details